Syngene posts ₹90 million Q1FY27 net loss as forex swings and termination costs hit
AI Market Summary
Syngene reported a Q1FY27 consolidated net loss of ₹90m versus a ₹867m profit a year earlier, driven by a large ₹501m FX fluctuation loss and ₹135m exceptional termination costs. Revenue fell 16% YoY and EBITDA margin compressed to 12.34% from 23.60%, highlighting weaker biologics demand and heightened currency sensitivity. Governance votes showed institutional pushback on a director appointment, adding scrutiny to leadership changes.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.25%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Syngene International reported a consolidated net loss of ₹90 million for Q1FY27 ended June 30, 2026, reversing a profit of ₹867 million a year earlier. The downturn was driven mainly by a ₹501 million foreign-exchange fluctuation loss and ₹135 million in exceptional termination benefits. Consolidated revenue fell 16% year on year to ₹7,360 million, while the operating EBITDA margin narrowed to 12.34% from 23.60%. The results point to pressure on profitability and higher sensitivity to currency moves.
